Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of BMS-908662 (XL281) Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer.

Next Previous
Search
Trial Profile

A Phase 1/2 Study of BMS-908662 (XL281) Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary) ; XL 281 (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; Biomarker
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 29 Sep 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 01 Jun 2011 Planned End Date changed from 1 Jan 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
  • 06 Jan 2011 Planned end date changed from 1 Jul 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top